• general@orthocell.com
  • +61 8 9360 2888
Orthocell Americas
  • Home
  • About
  • Team
  • Products
  • Invest
  • News
  • Practitioners
    • Striate+
    • Remplirâ„¢
    • OrthoACIâ„¢
    • Tendon
  • Contact
  • Region
    • Visit AU – Home
    • Visit Americas
    • Visit EU/UK
  • Home
  • About
  • Team
  • Products
  • Invest
  • News
  • Practitioners
    • Striate+
    • Remplirâ„¢
    • OrthoACIâ„¢
    • Tendon
  • Contact
  • Region
    • Visit AU – Home
    • Visit Americas
    • Visit EU/UK
09 Apr 2025
Orthocell Company News Permalink

Orthocell Receives Regulatory Approval for Striate+ in Brazil

Orthocell 9 April 2025

Orthocell has announced that Brazilian Health Regulatory Agency, ANVISA, has granted regulatory approval for the Company’s market-leading dental membrane, Striate+™, allowing the Company to commence sales in the large and important market of Brazil.

Read more

06 Apr 2025
Orthocell Media Permalink

MEDIA | 7 News

Orthocell 6 April 2025

Orthocell’s recent FDA clearance made headlines on 7 News this week, with journalist Alice Murray showcasing the human impact of our nerve repair technology.

Read more

05 Apr 2025
Orthocell Media Permalink

MEDIA | 9 News

Orthocell 5 April 2025

Orthocell welcomed 9 News journalist Michael Stamp to Orthocell HQ last week to film an in-depth segment about our FDA clearance for the nightly news.

Read more

04 Apr 2025
Orthocell Company News Permalink

US FDA grants 510(k) clearance for Orthocell’s flagship Remplir™ nerve repair product

Orthocell 4 April 2025

Orthocell has announced that the US Food and Drug Administration has granted regulatory clearance under the 510(k) pathway for the Company’s nerve repair product, Remplir™

Read more

26 Mar 2025
Orthocell Company News Permalink

First Sales of Striate+â„¢ in DACH Region

Orthocell 26 March 2025

Orthocell has today announced that our exclusive global distribution partner BioHorizons has officially completed first sales of Orthocell’s dental product, Striate+™, in Germany, Austria and Switzerland.

Read more

18 Mar 2025
Orthocell Company News Permalink

Orthocell Receives Regulatory Approval for Striate+ in Singapore

Orthocell 18 March 2025

Orthocell has received regulatory approval from Singapore’s Health Sciences Authority (HSA) for its market leading dental guided bone regeneration product, Striate+â„¢.

Read more

26 Feb 2025
Orthocell Video Permalink

REPLAY | Investor Webinar

Orthocell 26 February 2025

Orthocell CEO and MD, Paul Anderson, hosted a webinar this morning to provide an important update on Orthocell’s clinical and commercial plans.

Watch the replay:

21 Feb 2025
Orthocell Company News Permalink

Thailand Regulatory Application for Remplirâ„¢

Orthocell 21 February 2025

Orthocell has submitted a regulatory application to the FDA of Thailand to commence sales of its groundbreaking nerve repair device Remplirâ„¢, with clearance expected in Q3 CY2025.

Read more

03 Feb 2025
Orthocell Company News Permalink

Orthocell Submits Canada Regulatory Application to Commence Sales of Remplirâ„¢ into US$75million Canadian market

Orthocell 3 February 2025

Orthocell has announced it has submitted an application to Health Canada for a Medical Device Licence (MDL) to sell its leading nerve repair product Remplirâ„¢ into the US$75 million Canadian nerve repair market.

Read more

23 Jan 2025
Orthocell Media Permalink

Stockhead | Orthocell soars 14% after crushing early sales growth for Remplir

Orthocell 23 January 2025

Orthocell’s plans to broaden its commercial footprint in existing and new markets drove the company’s share price up 13.8% this week, according to a special report in Stockhead.

Read more

  • Recent posts

    • First US Surgical Use of Remplir™ 
    • Breakthrough Study Confirms Remplirâ„¢ Superiority Over Standard US Nerve Repair Technique
    • Stockhead | Interview with Dr Ian Valerio
    • The West Australian | Biotech’s easy cell to crack American market
    • Orthocell Receives Regulatory Approval for Remplirâ„¢ in Hong Kong
Previous
Next
  • © Orthocell Ltd. All rights reserved.

  • Contact Us

  • P: +61 8 9360 2888
    F: +61 8 9360 2899
    E: general@orthocell.com

  • News Updates

  • By entering your email address you are agreeing to our privacy policy.

BUILT WITH ♡ BY H^CK Orthocell Americas POWERED BY United Themes™
Please select the country you would like to view

Visit AU – Home

Visit Americas

Visit EU/UK

Join our mailing list

    By entering your email address you are agreeing to our privacy policy.


    Sign up to our EDM

    By entering your email address you are agreeing to our privacy policy.

    Patient expression of interest